-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KLMq/rDbulGRMHTeW/N8dGrWhHOeOkC4UMvXyVpzK1DhsWBQzgTmBrji9wu46YJ5 pzlWccW8LZAij5cYZZNkrA== 0000950152-03-009342.txt : 20031106 0000950152-03-009342.hdr.sgml : 20031106 20031106080022 ACCESSION NUMBER: 0000950152-03-009342 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20031105 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20031106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOPROBE CORP CENTRAL INDEX KEY: 0000810509 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 311080091 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26520 FILM NUMBER: 03980963 BUSINESS ADDRESS: STREET 1: 425 METRO PLACE N STREET 2: STE 400 CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147937500 MAIL ADDRESS: STREET 1: 425 METRO PLACE NORTH STREET 2: SUITE 400 CITY: DUBLIN STATE: OH ZIP: 43017 8-K 1 l04020ae8vk.txt NEOPROBE CORPORATION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT: NOVEMBER 5, 2003 NEOPROBE CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 0-26520 31-1080091 - ------------------ ---------------------- ------------------- (STATE OR OTHER (COMMISSION FILE NO.) (IRS EMPLOYER JURISDICTION OF IDENTIFICATION INCORPORATION OR NUMBER) ORGANIZATION) 425 Metro Place North, Suite 300 Columbus, Ohio 43017 (614) 793-7500 (ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER INCLUDING AREA CODE OF REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES) Not Applicable (FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT) ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (c) EXHIBITS. Exhibit No. Description 99 Neoprobe Corporation press release dated November 5, 2003. ITEM 9. REGULATION FD DISCLOSURE. On November 5, 2003, Neoprobe Corporation (the "Company") issued a press release regarding the interview of David C. Bupp, the Company's President and Chief Executive Officer by Wall Street Reporter, an online business news service. A copy of the Company's press release is furnished as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99 furnished herewith, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liability of that Section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as otherwise stated in such filing. Statements contained or incorporated by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's limited revenues, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and exclusive distributor, uncertainty of market acceptance, competition, limited marketing and manufacturing experience, and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOPROBE CORPORATION Date: November 5, 2003 By: /s/Brent L. Larson -------------------------- Brent L. Larson Vice President, Finance and Chief Financial Officer EXHIBIT INDEX Exhibit No. Description 99 Neoprobe Corporation press release dated November 5, 2003. EX-99 3 l04020aexv99.txt EXHIBIT 99 IMMEDIATE RELEASE NOVEMBER 5, 2003 CONTACTS: BRENT L. LARSON, JONATHAN FASSBERG, VP FINANCE & CFO THE TROUT GROUP 614 793 7500 212 437 9007 - ------------------------------------------------------------------------------ NEOPROBE'S CEO INTERVIEWED BY WALLSTREETREPORTER.COM DUBLIN, OHIO - November 5, 2003 -- Neoprobe Corporation (OTCBB: NEOP), today announced that its President and Chief Executive Officer, David C. Bupp, was interviewed by Wall Street Reporter, an online business news service. In the interview, Mr. Bupp briefly discussed Neoprobe's current development activities including those relating to the Company's line of gamma detection devices, its line of QuantixTM blood flow measurement devices, and its lymphatic mapping radiotracer Lymphoseektm. Among the highlights covered by Mr. Bupp were recent clinical presentations on the Quantix/NDtm and Quantix/ORtm products and a discussion of Lymphoseek's longer term revenue potential of approximately $30 - - 40 million annually. Mr. Bupp concludes the interview with a brief investment overview for the Company. To listen to Mr. Bupp's interview, go to www.wallstreetreporter.com. First-time users to Wall Street Reporter will have to register to listen to the interview. Scroll down to in the interviews dialog box to Neoprobe Corporation, David Bupp, and then click on the title. ABOUT NEOPROBE Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe's current line of gamma detection systems is widely used for intraoperative lymphatic mapping (ILM), an emerging standard of care technology for breast cancer and melanoma. Neoprobe also holds significant interests in the development of related biomedical systems and agents. The Company's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. With the acquisition of Cardiosonix Ltd. in 2001, Neoprobe expanded its product portfolio to include blood flow measurement products. Cardiosonix is a development stage company that has recently received regulatory clearance to begin the clinical evaluation and commercial sale of its blood flow measurement products. Cardiosonix' products (the Quantix/NDTM and the Quantix/ORTM) are designed to be used by neurosurgeons, cardiovascular surgeons and critical care physicians. Statements in this news release and the interview, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and exclusive distributor, competition, limited marketing and manufacturing experience, and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements. -----END PRIVACY-ENHANCED MESSAGE-----